David Hale - Conatus Pharmaceuticals Insider

CNAT -- USA Stock  

USD 4.49  0.16  3.44%

Independent Chairman of the Board
Mr. David F. Hale is the Independent Chairman of the Board of Conatus Pharmaceuticals Inc. Since May 2006, he has served as Chairman CEO of Hale BioPharma Ventures. He was previously President and CEO of CancerVax Corporationrationration which merged with Micromet, Inc from October 2000 through May 2006, when he became Chairman of the combined companies. He is a serial entrepreneur who was involved in the founding andor development of a number of biotechnology and specialty pharmaceutical companies. After joining Hybritech, Inc., in 1982, he was President Chief Operating Officer and became CEO in 1986. From 1987 to 1997 he was Chairman, President and CEO of Gensia, Inc. He was a cofounder and Chairman of Viagene, Inc. from 1987 to 1995. He was President and CEO of Women First HealthCare, Inc. from late 1997 to June 2000. Prior to joining Hybritech, he was Vice President and General Manager of BBL Microbiology Systems and from 1971 to 1980, held various marketing and sales management positions with Ortho Pharmaceutical Corporationrationration, a division of Johnson Johnson, Inc. Mr. Hale is Chairman of Santarus, Inc and previously served as Chairman of Somaxon, Inc. prior to its acquisition in 2013. He also serves as Chairman of Colorescience, Inc., Ridge Diagnostics, Crisi, Inc., Intrepid Therapeutics, Neurelis, Inc., Agility Clinical, Advantar Laboratories, Inc. and Katama Pharmaceuticals, Inc. He also is a cofounder and serves on the Board of Directors of BIOCOM, is a former member of the Board of the Biotechnology Industry Organization, and the Biotechnology Institute. He also serves on the Board of Directors of the San Diego Economic Development Corporationrationration, and as Chairman of the Board of Trustees of Rady Childrens Hospital of San Diego. He is a cofounder of the CONNECT Program in Technology and Entrepreneurship
Age: 66  Chairman Since 2012      
858-376-2600  http://www.conatuspharma.com
Hale holds a B.A. in Biology and Chemistry from Jacksonville State University.

David Hale Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (14.76) % which means that it has lost $14.76 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (87.78) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 13.34 M in liabilities with Debt to Equity (D/E) ratio of 57.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Conatus Pharmaceuticals has Current Ratio of 2.36 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. The company was founded in 2005 and is headquartered in San Diego, California. Conatus Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 33 people.Conatus Pharmaceuticals (CNAT) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 33 people. Conatus Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Conatus Pharmaceuticals Leadership Team

Edward Smith, President, MBA
Michelle Vandertie, Executive
Dan Kisner, Director
James Scopa, Director
Steven Mento, CEO
Daniel Kisner, Director
Preston Klassen, Director
David Hale, Chairman
Harold Wart, Director, Ph.D
William LaRue, Director, MBA
Alfred Spada, Founder, Ph.D
Charles Cashion, President, MBA
Daniel Ripley, President, MBA
Keith Marshall, President, MBA
Louis Lacasse, Director, MBA
Shahzad Malik, Director
David Hagerty, President

Stock Performance Indicators

Current Sentiment - CNAT

Conatus Pharmaceuticals Investor Sentiment
Most of Macroaxis users are currently bullish on Conatus Pharmaceuticals. What is your opinion about investing in Conatus Pharmaceuticals? Are you bullish or bearish?
98% Bullish
2% Bearish

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Conatus Pharmaceuticals and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Fundamentals Matrix module to view fundamentals matrix and analyze how accounts are interrelated and interconnected with each other.